Takeda to cease anti-diabetes compound research

Thu, 07 Sep 2006
Takeda Pharmaceutical, one of the leading diabetes drug companies in Japan, revealed on Thursday that they would cease developing one of their anti-diabetes compounds.

The company cited several reasons for the U-turn, including fears of the safety of the agent and concerns over its efficacy when compared to other existing drugs. The agent, known as TAK-654, had reached phase 2 clinical development in Japan, Europe and the US.

Takeda released a written statement explaining their decision: "Based on the thorough review of the pre-clinical and clinical data obtained to date, Takeda concluded that the TAK-654 does not show enough safety and efficacy profile, as compared to existing drugs, to support continuation of further development activities ."

The move by Takeda is likely to cost the company considerable amounts. When potential blockbuster drugs fail, the cost of the development can run far into the millions, both in money already expended and lost revenue from potential sales .

In other news, Takeda said that they would buy back a small percentage of its total issued common shares .
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
or
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.